Shanghai Junshi Biosciences (HKG:1877) said China's National Medical Products Administration (NMPA) issued a Drug Registration Certificate for toripalimab, the company's new drug for breast cancer treatment, according to a Tuesday filing on the Hong Kong bourse.
Toripalimab, which goes by the trade name of TUOYI, in combination with paclitaxel for injection (albumin-bound) is meant to be the first-line treatment of recurrent or metastatic triple-negative breast cancer.
The pharmaceutical company's shares rose 8% recently.
Price (HKD): $12.00, Change: $+0.92, Percent Change: +8.30%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments